Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1782

a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan

9:00AM-11:00AM: Abstract Number: 1810

A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort

9:00AM-11:00AM: Abstract Number: 1800

A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile

9:00AM-11:00AM: Abstract Number: 1804

Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis

9:00AM-11:00AM: Abstract Number: 1843

Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares

9:00AM-11:00AM: Abstract Number: 1785

Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1781

Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1819

Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1818

Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1811

Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1783

Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain

9:00AM-11:00AM: Abstract Number: 1791

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study

9:00AM-11:00AM: Abstract Number: 1814

Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients

9:00AM-11:00AM: Abstract Number: 1807

Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1808

Exercise Is Associated with Improved Cardiometabolic Risk Factors in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1805

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1829

Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling

9:00AM-11:00AM: Abstract Number: 1840

How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?

9:00AM-11:00AM: Abstract Number: 1815

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

9:00AM-11:00AM: Abstract Number: 1802

Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population

9:00AM-11:00AM: Abstract Number: 1801

Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice

9:00AM-11:00AM: Abstract Number: 1806

Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

9:00AM-11:00AM: Abstract Number: 1799

IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection

9:00AM-11:00AM: Abstract Number: 1786

Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE

9:00AM-11:00AM: Abstract Number: 1789

Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register

9:00AM-11:00AM: Abstract Number: 1831

Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1787

Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1797

Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain

9:00AM-11:00AM: Abstract Number: 1793

Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1838

Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study

9:00AM-11:00AM: Abstract Number: 1821

Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study

9:00AM-11:00AM: Abstract Number: 1788

Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1816

Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1795

Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-

9:00AM-11:00AM: Abstract Number: 1841

Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center Study

9:00AM-11:00AM: Abstract Number: 1833

Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis

9:00AM-11:00AM: Abstract Number: 1790

Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1817

Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain

9:00AM-11:00AM: Abstract Number: 1813

Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production

9:00AM-11:00AM: Abstract Number: 1792

Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review

9:00AM-11:00AM: Abstract Number: 1825

Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification

9:00AM-11:00AM: Abstract Number: 1830

Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors

9:00AM-11:00AM: Abstract Number: 1822

Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus

9:00AM-11:00AM: Abstract Number: 1827

Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLE

9:00AM-11:00AM: Abstract Number: 1837

Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study

9:00AM-11:00AM: Abstract Number: 1820

Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1796

Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 1798

Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE

9:00AM-11:00AM: Abstract Number: 1809

Real Life Implementation of Lupus Nephritis Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1832

Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 1844

Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1839

Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion

9:00AM-11:00AM: Abstract Number: 1803

Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 1826

Small LDL-P Increases with Increased Disease Activity in SLE

9:00AM-11:00AM: Abstract Number: 1836

Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1842

Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique

9:00AM-11:00AM: Abstract Number: 1835

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement

9:00AM-11:00AM: Abstract Number: 1828

Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1812

The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1834

Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?

9:00AM-11:00AM: Abstract Number: 1784

Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine

9:00AM-11:00AM: Abstract Number: 1824

Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1794

Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients

9:00AM-11:00AM: Abstract Number: 1823

Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].